Associate Professor of Surgery
473 W. 12th Ave., Suite 611B
Columbus, OH 43210
Epigenetic mechanisms in vascular disease, neurodegeneration in the retina, translational drug delivery into the vasculature and eye.
Treatments for cardiovascular disease, including angioplasty and bypass, frequently fail primarily because of the transition of normal vascular cells to a disease state. We have recently identified a molecular switch that, when pharmacologically turned off, halts the disease-prone cellular transition. This BET family of epigenetic “readers” couple with transcription factors to co-activate the expression of a select set of genes that in concert drive cell state transition. Via ChIPseq/RNAseq and transgenic animal models, we are investigating the disease mechanisms dictated by these epigenetic regulators invascular cells and lesions. Our lab is also exploiting the neuroprotective potential of the sigma-1 receptor chaperone in retinal neurodegeneration. With ongoing translational efforts, we hope our research will ultimately lead to effective treatments for large populations, who would otherwise develop flow-obstructing vascular diseases or blindness.
PhD: Shanghai Institute of Plant Physiology, Chinese Academy of Sciences